Last updated: 2026-09-05 02:03:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Natera, Inc. (NTRA) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $328.28, with a market capitalization of $46.87B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $157.43 to $343.18. This page covers its latest market performance, valuation, price trends and company information.
$46.87B | |
$323.92 | |
$343.18 | |
$6.52 | |
$327.67 | |
702.46K | |
-- | |
-- | |
$343.18 | |
$157.43 | |
-- | |
-- |
Natera, Inc. (NTRA) last closed at $327.67 as of 2026-09-04 23:49:00, unchanged from the previous close of $327.67.
During the latest regular trading session, NTRA traded between $6.52 and $343.18, with a volume of 702.46K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Natera, Inc. (NTRA) moved from $320.95 to $328.28, representing a gain of 2.28% ($7.33).
The stock traded between $323.86 and $329.17 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 973.37 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 92.0%
NTRA is currently trading at $328.28, placing it 92.0% of the way from its 52-week low of $157.43 to its 52-week high of $343.18. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 6140 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Natera, Inc. (NTRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.